-

Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia

$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced $97 million investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.

The current laboratory services operation in Richmond, which Thermo Fisher acquired through the purchase of PPD, Inc. in December 2021, now comprises more than 350,000 square feet, making it one of the largest laboratories of its kind in the world. The entire Richmond operation employs about 1,300 local professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals. The bulk of the expansion with this new facility will occur in liquid chromatography-mass spectrometry for drug discovery through to clinical testing, as well as subsequent enhancements in cell and gene therapy, biomarkers, vaccine sciences and immunochemistry.

“The ongoing expansion of our bioanalytical operations builds on the growth of our drug development expertise over nearly four decades, enabling us to provide customers with high-quality lab services to advance their clinical research programs,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “These additions will enable us to meet the growing needs of our customers delivering life-changing therapies. We are thankful for the support this project has received from leaders in Virginia, Henrico County and Richmond.”

Virginia Governor Glenn Youngkin said, “Congratulations to Thermo Fisher on the unveiling of their new clinical research laboratory. As a world leader in the scientific field, we welcome their growing expansion in the Commonwealth. Their announcement is a testament to what the Commonwealth can offer for a growing company: a great workforce, economic development tools and abundant resources.”

The Richmond bioanalytical lab, elements of which have been operating since 1985, provides services for all phases of biopharmaceutical development for small molecule drugs, biologics, vaccines and biomarker testing. Drug testing services include drug pharmacokinetics and pharmacodynamics (PK/PD), immunogenicity and biomarker quantitation to support drug efficacy and safety.

In addition to bioanalytical, biomarker and vaccine sciences labs in Richmond, Thermo Fisher’s clinical research business includes bioanalytical and good manufacturing practices (GMP) labs in Middleton, Wisconsin; a GMP lab in Athlone, Ireland; central labs and biomarker operations in Brussels, Belgium, Highland Heights, Kentucky, and Singapore; and bioanalytical, biomarker, vaccine sciences and central labs in Suzhou, China.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Randy Buckwalter
Thermo Fisher Scientific
919-456-4425
randy.buckwalter@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia
Release Versions

Contacts

Media Contact Information:
Randy Buckwalter
Thermo Fisher Scientific
919-456-4425
randy.buckwalter@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies. Accelerating Drug Discovery with Cryo-EM The...

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may...
Back to Newsroom